The deal is aimed at developing new drugs that can benefit the large population of people with unmet needs in the pain management area.
Under the deal, Jubilant’s experience in drug discovery and pre-clinical development will be used by Orion to address pain management needs of Central Nervous System (CNS).
Jubilant will also provide integrated drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services.
The research for the project, which has been started, will be undertaken primarily at Jubilant Biosys’ R&D labs and some parts at Jubilant Discovery Center in US.
Jubilant Biosys president Subir Kumar Basak said the company is happy to partner with Orion to offer integrated drug discovery services.
"Over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts," Basak said.
"We are confident of offering successful results to Orion at various stages of research."
Orion Pharma head of CNS Research and R&D Jukka Sallinen said Jubilant Biosys is widely recognised for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation.
"With established ability to develop successful drugs, we consider Jubilant as our ideal partner to take forward our strategic business plans with optimum time-to-market and accuracy," Sallinen said.
According to a pre-defined research plan, Jubilant will receive research funding from Orion for delivering Hit, Lead Generation and Optimization milestone.
Under the royalty based alliance, Orion will offer royalty to Jubilant and will retain ownership of the compounds developed under the deal with exclusive worldwide rights.